Finally given the inability to rescue defects induced by targeting CaMKK2 with either CAMKIV overexpression in liver cancer or with AMPK activators in prostate cancer [28], it will be important to determine whether COPI coatomer subunit overexpression can rescue defects in these or other disease settings. This evidence concerns the gene CAMKK2 and prostate carcinoma.